Primary gastrointestinal non-Hodgkin's lymphoma: A clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG)
dc.contributor.author | Papaxoinis, G. | en |
dc.contributor.author | Papageorgiou, S. | en |
dc.contributor.author | Rontogianni, D. | en |
dc.contributor.author | Kaloutsi, V. | en |
dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Dimopoulos, M. A. | en |
dc.contributor.author | Tsatalas, C. | en |
dc.contributor.author | Xiros, N. | en |
dc.contributor.author | Economopoulos, T. | en |
dc.creator | Papaxoinis, G. | en |
dc.creator | Papageorgiou, S. | en |
dc.creator | Rontogianni, D. | en |
dc.creator | Kaloutsi, V. | en |
dc.creator | Fountzilas, George | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Dimopoulos, M. A. | en |
dc.creator | Tsatalas, C. | en |
dc.creator | Xiros, N. | en |
dc.creator | Economopoulos, T. | en |
dc.date.accessioned | 2018-06-22T09:54:10Z | |
dc.date.available | 2018-06-22T09:54:10Z | |
dc.date.issued | 2006 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42219 | |
dc.description.abstract | The aim of this retrospective study was to illustrate the clinicopathologic data and the treatment results in patients with primary gastrointestinal tract non-Hodgkin's lymphoma (GI NHL). Among 810 patients with NHL, 128 cases (15.8%) were diagnosed as primary GI tract NHL. There were 79 males and 49 females with median age of 62 years. The most common primary site was the stomach (68%). Overall, 67.2% of the patients were in stages I-II, and 32.8% in stages III-IV. Simultaneous involvement of the GI tract and other extranodal sites was observed in 26 patients (20%). Extranodal marginal zone B-cell lymphoma (MZBL) (i.e., low-grade lymphoma of mucosa-associated lymphoid tissue type) accounted for 48.4% of lymphomas. Aggressive lymphomas (diffuse large B-cell lymphoma [DLBL]) accounted for 44.5%. Eighty-three patients (67.5%) achieved complete response (CR), either by surgery (43/ 43 patients, 17 with DLBL and 25 with MZBL) or by primary chemotherapy (40/64 patients, 22 with DLBL and 17 with MZBL). Sixty-two patients remain in CR; 33/43 after surgical resection (13/17 with DLBL and 20/25 patients with MZBL), and 29/40 after only chemotherapy (18/22 with DLBL and 10/17 with MZBL). The major prognostic factor for outcome in the present study was the stage of the disease. Patients with localized lymphoma (stage I and II) had significantly longer DFS and OS (DFS and OS at 3-year: 83% and 87%, respectively) than patients with extended disease (stage III and IV) (DFS and OS at 3-year: 46% and 60%, respectively) (P < 0.0001). The International Prognostic Index (IPI) for patients with aggressive lymphomas was prognostic only for DFS (79% for low-risk patients [IPI score 0-1] vs 49% for higher risk groups [IPI score 0-1] at 3-year, P = 0.0131). | en |
dc.language.iso | eng | en |
dc.source | Leukemia and Lymphoma | en |
dc.subject | Greece | en |
dc.subject | Article | en |
dc.subject | Bleomycin | en |
dc.subject | Cyclophosphamide | en |
dc.subject | Cytarabine | en |
dc.subject | Doxorubicin | en |
dc.subject | Etoposide | en |
dc.subject | Human | en |
dc.subject | Methotrexate | en |
dc.subject | Vincristine | en |
dc.subject | 80 and over | en |
dc.subject | Aged | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Major clinical study | en |
dc.subject | Middle aged | en |
dc.subject | Advanced cancer | en |
dc.subject | Cancer combination chemotherapy | en |
dc.subject | Cancer survival | en |
dc.subject | Priority journal | en |
dc.subject | Prognosis | en |
dc.subject | Disease-free survival | en |
dc.subject | Gemcitabine | en |
dc.subject | Navelbine | en |
dc.subject | Cancer staging | en |
dc.subject | Disease free survival | en |
dc.subject | Treatment outcome | en |
dc.subject | Time factors | en |
dc.subject | Overall survival | en |
dc.subject | B cell lymphoma | en |
dc.subject | Mitoxantrone | en |
dc.subject | Nonhodgkin lymphoma | en |
dc.subject | Epirubicin | en |
dc.subject | Folinic acid | en |
dc.subject | Male | en |
dc.subject | Risk assessment | en |
dc.subject | Clinical feature | en |
dc.subject | Large cell lymphoma | en |
dc.subject | Lymphoma | en |
dc.subject | Cancer risk | en |
dc.subject | High risk patient | en |
dc.subject | Cancer adjuvant therapy | en |
dc.subject | Gastrointestinal neoplasms | en |
dc.subject | Digestive system cancer | en |
dc.subject | Treatment response | en |
dc.subject | Cancer localization | en |
dc.subject | Rituximab | en |
dc.subject | Non-hodgkin | en |
dc.subject | Adolescent | en |
dc.subject | Fludarabine | en |
dc.subject | Extranodal | en |
dc.subject | Mucosa associated lymphoid tissue lymphoma | en |
dc.subject | Chlorambucil | en |
dc.subject | Anthracycline | en |
dc.subject | Scoring system | en |
dc.subject | Intestinal | en |
dc.subject | Stomach | en |
dc.title | Primary gastrointestinal non-Hodgkin's lymphoma: A clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG) | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1080/10428190600709226 | |
dc.description.volume | 47 | |
dc.description.issue | 10 | |
dc.description.startingpage | 2140 | |
dc.description.endingpage | 2146 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |